

PTO8 Rec'd PCT/PTO 14 MAR 2005

PCT  
#5

PTO/SB/82 (09-04)

Approved for use through 11/30/2005. OMB 0651-0035  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF  
ATTORNEY WITH  
NEW POWER OF ATTORNEY  
AND  
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	10/509,941
Filing Date	October 1, 2004
First Named Inventor	Elaine, Sophie, Elizabeth Stokes
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	100690-1P US

I hereby revoke all previous powers of attorney given in the above-identified application.

A Power of Attorney is submitted herewith.

OR

I hereby appoint the practitioners associated with the Customer Number:

44992

Please change the correspondence address for the above-identified application to:

The address associated with  
Customer Number:

44992

OR

<input type="checkbox"/> Firm or Individual Name	AstraZeneca Pharmaceuticals LP Carol A Loeschorn
---	---

Address	Global Intellectual Property 35 Gatehouse Drive
---------	--

City	Waltham	State	MA	Zip	02451
------	---------	-------	----	-----	-------

Country	USA
---------	-----

Telephone	781 839 4002	Fax	781 893 4121
-----------	--------------	-----	--------------

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Signature	<i>Kevin Bill</i>		
Name	KEVIN BILL		
Date	18 March 2005	Telephone	+1 44 1625 512461

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

\*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**BEST AVAILABLE COPY**



Rec'd PCT/PTO 14 MAR 2005

PTO/SB/96 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: STOKES et al.

Application No./Patent No.: 10/509,941 Filed/Issue Date: October 1, 2004

Entitled: **BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS**

AstraZeneca AB

(Name of Assignee)

a Corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest; or
2.  an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:


1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

  
\_\_\_\_\_  
Signature

KEVIN BILL

Printed or Typed Name

PATENT DIRECTOR, CV

Title

1 March 2005

Date

+141625512461

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**BEST AVAILABLE COPY**

**ASSIGNMENT**

For good and valuable consideration, receipt of which is hereby acknowledged, ASSIGNOR (S),

**STOKES, Elaine, Sophie, Elizabeth; ROBERTS, Craig, Anthony and WARING, Michael, James**

Hereby sell(s), assign(s) and transfer(s) to ASSIGNEE AstraZeneca AB, a company created and existing under the laws of Sweden, having its Head Office at SE-151 85 Sodertalje, Sweden, and the successors assign and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

**BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS**

And which is found in:

- (a)  U.S. patent application executed on even date herewith;
- (b)  U.S. patent application executed on \_\_\_\_\_;
- (c)  U.S. application serial no. Filed on \_\_\_\_\_;
- (d)  International application no. PCT/GB03/01442 filed on 02 April 2003 (02.04.2003).

And any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to Letters Patent or any reissue or reexamination thereof;

ASSIGNOR (S) hereby covenant(s) that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR (S) further covenant(s) that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

IN TESTIMONY WHEREOF, I/WE have hereunto set our hand(s).

Full Name of Sole or First Assignor <b>STOKES, Elaine, Sophie, Elizabeth</b>	Assignor's Signature <i>Elaine Sophie Elizabeth Stok</i>	Date <b>18<sup>th</sup> August 2003</b>
Address <b>AstraZeneca R&amp;D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG, England</b>	Citizenship: <b>Great Britain</b>	
Names of additional inventors attached <input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No	

**BEST AVAILABLE COPY**

Rec'd PCT/PTO 14 MAR 2005

ATTORNEY DOCKET NO.: 056291-  
AstraZeneca Ref.: 100690-IP US

Full Name of Seconder Assignor <b>ROBERTS, Craig, Anthony</b>	Assignor's Signature <i>Craig Anthony Roberts</i>	Date <i>18<sup>th</sup> August 2004</i>
Address AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG, England		Citizenship: Great Britain
Full Name of Third Assignor <b>WARING, Michael, James</b>	Assignor's Signature <i>Michael James Waring</i>	Date <i>18 August 2004</i>
Address AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG, England		Citizenship: Great Britain

BEST AVAILABLE COPY